Navigation Links
High-Dose Chemo Fails Against Small Cell Lung Cancers
Date:4/9/2008

Tripled dose was ineffective and toxic, so strategy should be abandoned, study says

WEDNESDAY, April 9 (HealthDay News) -- High-intensity chemotherapy does not improve the survival rate of patients with small cell lung cancer (SCLC), a new Swiss study concludes.

Testing on 140 patients in a randomized trial showed no statistically significant differences in survival rate or tumor size between groups receiving either standard or high doses of chemo over a three-year period. The findings were published online April 8 in the Journal of the National Cancer Institute.

Researchers thought upping the amount of chemotherapy might help the patients live longer because laboratory data had suggested that higher doses kill SCLC cells resistant to standard doses.

"The approach explored in the present trial succeeded in raising the peak dose, total dose and dose intensity of (the chemotherapy drugs) by threefold but has clearly been ineffective and highly toxic," the authors wrote. "As a result, this strategy should be abandoned."

SCLC accounts for almost 13 percent of lung cancer cases in the United States. While many patients initially respond to chemotherapy, most suffer disease recurrence relatively quickly.

The study, lead by Dr. Serge Leyvraz of the University Hospital in Lausanne, Switzerland, compared high-dose and standard-dose chemotherapy using the drug agents: ifosfamide, carboplatin and etoposide (ICE).

The survival rates in the group were similar: 18 percent of the high-dose patients were alive after three years, 19 percent of standard-dose patients survived. Tumor shrinkage was also similar in the two groups: 78 percent among the high-dose recipients and 68 percent in the standard-dose arm.

More information

The National Cancer Institute has more about lung cancer.



-- Kevin McKeever



SOURCE: Journal of the National Cancer Institute, news release, April 8, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
2. High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
3. High-Dose Chemo Helps Beat Rare Brain Cancer
4. Chemotherapy may be culprit for fatigue in breast cancer survivors
5. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
6. To evade chemotherapy, some cancer cells mimic stem cells
7. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
8. PET scans can accurately detect a breast tumors response to chemotherapy
9. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
10. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
11. Medicare modernization act did not change chemotherapy as feared
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 20, 2017 , ... United Benefit Advisors (UBA), the nation’s ... (pronounced you-bee) for 2017. The award honors Partner Firms, Principals, agency staff, ... the clients they serve, and the benefits insurance industry as a whole. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... Caduceus International Publishing ... to announce a new online course entitled Personal & Community Health ... evidence-based strategies for achieving optimal well-being and teaches students how to apply them ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
(Date:6/20/2017)... ... 20, 2017 , ... EdChoice and the American Enterprise Institute ... promote economic development in economically distressed urban areas. The first report presents a ... to the economic development of the city of Santa Ana, California. The second ...
(Date:6/20/2017)... New York, NY (PRWEB) , ... June 20, 2017 , ... ... announced today their continued expansion and success in the clinical trials market. Similar to ... building a track record in the clinical trials marketplace by proving the value of ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... -- The Bio Supply Management Alliance (BSMA) has announced ... and the Biomedical Manufacturing Network to advance the ... California by providing a platform for imparting ... development. The primary focus of this alliance is to ... as small and mid-sized biomedical companies. ...
(Date:6/10/2017)... 2017  Shane K. Burchfield, DPM, is recognized by Continental Who,s ... Podiatrist in Alabama . Dr. ... Care. He brings over 20 years of experience, as well as ... to his role. ... pleased to welcome you to his practice," the company,s ...
(Date:6/8/2017)... , June 8, 2017  StatLab ... leading developer and manufacturer of diagnostic supplies ... today that Cressey & Company LP ("Cressey ... has completed a growth-focused investment in the ... majority ownership position from selling shareholder, Prairie ...
Breaking Medicine Technology: